Patents by Inventor Shawn Lawrence

Shawn Lawrence has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Intermittent monitoring
    Patent number: 11998322
    Abstract: Various examples are directed to systems and methods for patient monitoring. An example method comprises receiving an estimated glucose concentration level of the patient from a continuous glucose monitoring (CGM) system for a first time period. The method may also include receiving non-glucose information relating to the patient for the first time period and determining a relationship between the estimated glucose concentration level and the non-glucose information. The method may also include receiving non-glucose information relating to the patient for a second time period and determining diabetic information about the patient for the second time period based upon the determined relationship and the non-glucose information. The method may include electronically delivering a notification about the diabetic information.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: June 4, 2024
    Assignee: Dexcom, Inc.
    Inventors: Apurv Ullas Kamath, Margaret A. Crawford, John Michael Gray, Hari Hampapuram, Matthew Lawrence Johnson, Subrai Girish Pai, Shawn Clay Sanders, Sumitaka Mikami
  • TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USE
    Publication number: 20240018467
    Abstract: The specification describes a composition comprising an improved eukaryotic cell culture medium, which can be used for the production of a protein of interest. TaXULne can be added to the serum-free media or chemically-defined media to incrase the production of a protein of interest. Methods for recombinantly expressing high levels of protein using the media compositions are included.
    Type: Application
    Filed: September 22, 2023
    Publication date: January 18, 2024
    Inventors: Amy S. Johnson, Meghan E. Casey, Shadia Oshodi, Shawn Lawrence
  • ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME
    Publication number: 20230357357
    Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
    Type: Application
    Filed: June 26, 2023
    Publication date: November 9, 2023
    Inventors: Shunhai Wang, Ning Li, Hunter Chen, Amardeep Singh Bhupender Bhalla, Shawn Lawrence, Amy Johnson, Meghan Casey, Jaimie Grapel
  • Anti-VEGF protein compositions and methods for producing the same
    Patent number: 11732025
    Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
    Type: Grant
    Filed: November 25, 2022
    Date of Patent: August 22, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Shunhai Wang, Ning Li, Hunter Chen, Amardeep Singh Bhupender Bhalla, Shawn Lawrence, Amy Johnson, Meghan Casey, Jaimie Grapel
  • ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME
    Publication number: 20230119662
    Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
    Type: Application
    Filed: November 25, 2022
    Publication date: April 20, 2023
    Inventors: Shunhai Wang, Ning Li, Hunter Chen, Amardeep Singh Bhupender Bhalla, Shawn Lawrence, Amy Johnson, Meghan Casey, Jaimie Grapel
  • ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME
    Publication number: 20230068199
    Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins.
    Type: Application
    Filed: July 6, 2022
    Publication date: March 2, 2023
    Inventors: Shunhai Wang, Ning Li, Hunter Chen, Amardeep Singh Bhupender Bhalla, Shawn Lawrence, Amy Johnson, Meghan Casey, Jamie Mastrogiacomo
  • VEGF MINI-TRAPS AND METHOD OF USE THEREOF
    Publication number: 20230063116
    Abstract: The present invention provides VEGF mini-trap molecules and method of treating or preventing angiogenic disorders such as angiogenic eye disorders and cancer.
    Type: Application
    Filed: December 4, 2020
    Publication date: March 2, 2023
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Joel MARTIN, Samuel DAVIS, Shawn LAWRENCE, Amy JOHNSON, Meghan CASEY, Jaimie MASTROGIACOMO, Shunhai WANG, Ning LI, Andrew TUSTIAN, Ankit VARTAK, Matthew FRANKLIN
  • Anti-VEGF protein compositions and methods for producing the same
    Patent number: 11548932
    Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
    Type: Grant
    Filed: June 15, 2022
    Date of Patent: January 10, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Shunhai Wang, Ning Li, Shawn Lawrence, Amy Johnson, Meghan Casey, Jaimie Grapel, Hunter Chen, Amardeep Singh Bhupender Bhalla
  • Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
    Patent number: 11535663
    Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
    Type: Grant
    Filed: July 22, 2021
    Date of Patent: December 27, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Shawn Lawrence, Amy Johnson, Meghan Casey, Jaimie Mastrogiacomo, Shunhai Wang, Ning Li
  • ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME
    Publication number: 20220389081
    Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
    Type: Application
    Filed: June 15, 2022
    Publication date: December 8, 2022
    Inventors: Shunhai Wang, Ning Li, Shawn Lawrence, Amy Johnson, Meghan Casey, Jamie Mastrogiacomo, Hunter Chen, Amardeep Singh Bhupender Bhalla
  • Anti-VEGF protein compositions and methods for producing the same
    Patent number: 11505594
    Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
    Type: Grant
    Filed: April 1, 2022
    Date of Patent: November 22, 2022
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Andrew Tustian, Ankit Vartak, Thomas Daly, Erica Pyles, Nisha Palackal, Shunhai Wang, Ning Li, Matthew Franklin, Shawn Lawrence, Amy Johnson, Meghan Casey, Jaimie Grapel
  • Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
    Patent number: 11472861
    Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: October 18, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Shawn Lawrence, Amy Johnson, Meghan Casey, Jaimie Mastrogiacomo, Shunhai Wang, Ning Li
  • METABOLICALLY OPTIMIZED CELL CULTURE
    Publication number: 20220315644
    Abstract: Improved methods for large scale production of proteins and/or polypeptides in cell culture is provided. In accordance with the present invention, the method provides for culturing cells that have metabolically shifted. The use of such a method or system allows high levels of protein or polypeptide production and reduces accumulation of unwanted metabolic waste such as lactate. Proteins and polypeptides expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical, immunogenic, or other commercial biologic compositions, such as antibodies.
    Type: Application
    Filed: June 17, 2022
    Publication date: October 6, 2022
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Shawn LAWRENCE, Michelle LAFOND, Ann KIM, Amy S. JOHNSON, Brandon VERES, Mark CZETERKO, Kristen WHALEN
  • Metabolically optimized cell culture
    Patent number: 11390663
    Abstract: Improved methods for large scale production of proteins and/or polypeptides in cell culture is provided. In accordance with the present invention, the method provides for culturing cells that have metabolically shifted. The use of such a method or system allows high levels of protein or polypeptide production and reduces accumulation of unwanted metabolic waste such as lactate. Proteins and polypeptides expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical, immunogenic, or other commercial biologic compositions, such as antibodies.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: July 19, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Shawn Lawrence, Michelle LaFond, Ann Kim, Amy S. Johnson, Brandon Veres, Mark Czeterko, Kristen Whalen
  • METHODS FOR PRODUCING AFLIBERCEPT IN CHEMICALLY DEFINED MEDIA HAVING REDUCED AFLIBERCEPT VARIANTS
    Publication number: 20220127331
    Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
    Type: Application
    Filed: December 21, 2021
    Publication date: April 28, 2022
    Inventors: Shawn Lawrence, Amy Johnson, Meghan Casey, Jaimie Mastrogiacomo, Shunhai Wang, Ning Li
  • Taurine supplemented cell culture medium and methods of use
    Patent number: 11312936
    Abstract: The specification describes a composition comprising an improved eukaryotic cell culture medium, which can be used for the production of a protein of interest. Taurine can be added to serum-free media or chemically-defined media to increase the production of a protein of interest. Methods for recombinantly expressing high levels of protein using the media compositions are included.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: April 26, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Amy S. Johnson, Meghan E. Casey, Shadia Oshodi, Shawn Lawrence
  • METHODS FOR PRODUCING AFLIBERCEPT IN CHEMICALLY DEFINED MEDIA HAVING REDUCED AFLIBERCEPT VARIANTS
    Publication number: 20220033471
    Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
    Type: Application
    Filed: July 22, 2021
    Publication date: February 3, 2022
    Inventors: Shawn Lawrence, Amy Johnson, Meghan Casey, Jaimie Mastrogiacomo, Shunhai Wang, Ning Li
  • CELL CULTURE PROCESS FOR MAKING A GLYCOPROTEIN
    Publication number: 20210388408
    Abstract: The instant application provides a method for screening batches of soy hydrolysate for a desired amount of a component thereof, such as ornithine or putrescine, and selecting only those batches of soy hydrolysate that have a desired amount of such component. The present disclosure also sets forth methods for culturing cells in media supplemented with selected batches of soy to produce more consistent, high quality lots of a protein of interest. Further, the present disclosure provides a plurality of protein preparations that have each been produced by culturing cells in media supplemented with separate batches of soy hydrolysate containing a desired amount of ornithine or putrescine, whereby each batch of protein produced exhibits improved quality of the protein of interest or amount of quality protein produced.
    Type: Application
    Filed: August 23, 2021
    Publication date: December 16, 2021
    Inventors: John CHEN, Shawn LAWRENCE, Amy JOHNSON, Theodore LONEY, Ravindra PANGULE, Ta-Chun HANG, Scott CARVER, Bernhard SCHILLING
  • CELL CULTURE PROCESS FOR MAKING A GLYCOPROTEIN
    Publication number: 20210388407
    Abstract: The instant application provides a method for screening batches of soy hydrolysate for a desired amount of a component thereof, such as ornithine or putrescine, and selecting only those batches of soy hydrolysate that have a desired amount of such component. The present disclosure also sets forth methods for culturing cells in media supplemented with selected batches of soy to produce more consistent, high quality lots of a protein of interest. Further, the present disclosure provides a plurality of protein preparations that have each been produced by culturing cells in media supplemented with separate batches of soy hydrolysate containing a desired amount of ornithine or putrescine, whereby each batch of protein produced exhibits improved quality of the protein of interest or amount of quality protein produced.
    Type: Application
    Filed: August 23, 2021
    Publication date: December 16, 2021
    Inventors: John CHEN, Shawn LAWRENCE, Amy JOHNSON, Theodore LONEY, Ravindra PANGULE, Ta-Chun HANG, Scott CARVER, Bernhard SCHILLING
  • Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
    Patent number: 11104715
    Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: August 31, 2021
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Shawn Lawrence, Amy Johnson, Meghan Casey, Jaimie Mastrogiacomo, Shunhai Wang, Ning Li